Effects and mechanisms of Supplemented Gegen Qinlian Decoction Formula against podocyte pyroptosis and insulin resistance in model rats with diabetic kidney disease.
10.19540/j.cnki.cjcmm.20210524.406
- Author:
Mei-Zi WANG
1
;
Li-Jun YUE
2
;
Yi-Gang WAN
2
;
Huang HUANG
3
;
Wei WU
2
;
Yue TU
4
;
Bu-Hui LIU
5
;
Qi-Jun FANG
1
;
Can-Can YUAN
1
;
Jie WANG
1
;
Huan LI
1
;
Zi-Yue WAN
6
Author Information
1. Department of Traditional Chinese Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine Nanjing 210008, China.
2. Department of Traditional Chinese Medicine, Nanjing Drum Tower Hospital,The Affiliated Hospital of Medical School of Nanjing University Nanjing 210008, China.
3. School of International Classical Prescription, Nanjing University of Chinese Medicine Nanjing 210023, China.
4. School of Acupuncture-Moxibustion and Tuina&School of Health Preservation and Rehabilitation, Nanjing University of Chinese Medicine Nanjing 210023, China.
5. Department of Nephrology, Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing 210029, China.
6. Graduate School of Social Sciences, Faculty of Social Sciences, Hitotsubashi University Tokyo 186-8601, Japan.
- Publication Type:Journal Article
- Keywords:
Supplemented Gegen Qinlian Decoction Formula;
diabetic kidney disease;
insulin resistance;
insulin signaling pathway;
podocyte pyroptosis
- MeSH:
Animals;
Diabetes Mellitus;
Diabetic Nephropathies/drug therapy*;
Drugs, Chinese Herbal;
Insulin Resistance;
Podocytes;
Pyroptosis;
Rats
- From:
China Journal of Chinese Materia Medica
2021;46(17):4471-4479
- CountryChina
- Language:Chinese
-
Abstract:
This study explored the in vivo effects and mechanisms of the modern classical prescription Supplemented Gegen Qinlian Decoction Formula(SGDF) against diabetic kidney disease(DKD). Sixty rats were randomly divided into the normal group, model group, SGDF group, and rosiglitazone(ROS) group. The modified DKD rat model was established by employing the following three methods: exposure to high-fat diet, unilateral nephrectomy, and intraperitoneal injection of streptozotocin(STZ). After modeling, rats in the four groups were treated with double distilled water, SGDF suspension, and ROS suspension, respectively, by gavage every day. At the end of the 6 th week of drug administration, all the rats were sacrificed for collecting urine, blood, and kidney tissue, followed by the examination of rat general conditions, urine and blood biochemical indicators, glomerulosclerosis-related indicators, podocyte pyroptosis markers, insulin resistance(IR)-related indicators, and key molecules in the insulin receptor substrate(IRS) 1/phosphatidylinositol-3-kinase(PI3 K)/serine threonine kinase(Akt) signaling pathway. The results showed that SGDF and ROS improved the general conditions, some renal function indicators and glomerulosclerosis of DKD model rats without affecting the blood glucose(BG). Besides, they ameliorated the expression characteristics and levels of podocyte pyroptosis markers, alleviated IR, and up-regulated the protein expression levels of the key molecules in IRS1/PI3 K/Akt pathway to varying degrees. In conclusion, similar to ROS, SGDF relieves DKD by targeting multiple targets in vivo. Specifically, it exerts the therapeutic effects by alleviating podocyte pyroptosis and IR. This study has preliminarily provided the pharmacological evidence for the research and development of new drugs for the treatment of DKD based on SGDF.
